Highlights

MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

Archivi del mese: ottobre 2021

MP-LG1&LG2

LG1 & LG2 are human recombinant therapeutic proteins which  represent an innovative treatment for Non-Healing Wounds and Peripheral Arterial Disease.

Scientists at MediaPharma have discovered recombinant proteins, named LG1 & LG2, which accelerate wound healing through stimulation of angiogenesis and adhesion via an innovative mechanism.

MediaPharma is sought to develop an application of these products in:

  • Diabetic foot ulcers
  • Non-healing surgical wounds
  • Wounds related to metabolic diseases
  • Wounds that repeatedly break down

Company

R&D

Careers

Business